Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nicotine abuse vaccine - Biota Pharmaceuticals

Drug Profile

Nicotine abuse vaccine - Biota Pharmaceuticals

Alternative Names: 3'-aminomethyl-Nic r-EPA Conjugate; Nicotine conjugate vaccine - Nabi Biopharmaceuticals; NicVAX

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nabi Biopharmaceuticals
  • Developer Aktiv-Dry; Aviragen Therapeutics; Nabi Biopharmaceuticals
  • Class Drug withdrawal therapies; Smoking cessation therapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Smoking withdrawal

Most Recent Events

  • 08 Nov 2012 Biota Holdings has merged with Nabi Biopharmaceuticals to form Biota Pharmaceuticals
  • 17 Oct 2012 Efficacy and adverse events data from a phase II trial in Smoking withdrawal reported by Nabi Biopharmaceuticals
  • 11 May 2012 Nabi Biopharmaceuticals completes a phase III trial in Smoking withdrawal in USA (NCT01375933)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top